XNCR at a glance
Xencor Inc (XNCR, SEC CIK 1326732) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Xencor Inc (XNCR) reported revenue of $125.6 million (up 13.7% from FY2024) and a net loss of $91.9 million. Diluted EPS was -$1.24.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Xencor Inc (XNCR) shares worth $865.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cornelissen Bart Jan on November 11, 2026 of 10,100 shares at $39.82 per share.
- In the last 90 days, XNCR insiders reported 0 open-market purchases ($0) and 3 open-market sales ($3.6M) on Form 4, a net sale of $3.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $125.6M
- +13.7% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$3.6M
- 13F holders
- 31 funds
- $865.9M · +0 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Clinical-stage biopharma developing engineered XmAb antibody therapeutics targeting cancer and autoimmune diseases with modular bispecific Fc domain technology
- New product emphasis: XmAb412, a bispecific antibody targeting TL1A and IL23p19 in autoimmune diseases, first-in-human studies planned for 2026
- Strategic shift: Prioritization of T cell-engaging bispecific antibody programs in oncology, expanding XmAb 2+1 bispecific format applications in solid tumors
- Quantitative metric: Phase 1 XmAb819 RCC study enrolled 69 patients, 25% partial response rate, 70% disease control rate; XmAb942 Phase 2b initiated in ulcerative colitis
- Noteworthy fact: Collaboration revenues include $70.1M royalties from Alexion’s Ultomiris and $10.2M from Incyte’s Monjuvi in 2025, highlighting growing partner-generated income
Risk Factors
- Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates
- Geopolitical/macro risk from California concentration; wildfires or earthquakes could disrupt operations and third-party supply continuity
- Supply chain vulnerability relying on third-party manufacturers, contract research organizations, and collaborators for manufacturing and clinical execution
- Competitive risk from other biotech/pharma firms with new products and technologies impacting market position and stock volatility
- Financial risk of significant net loss $91.9M in 2025, accumulated deficit $796.0M, requiring additional financing beyond $610.8M cash reserves to fund operations through 2028
Management Discussion & Analysis
- Revenue $125.6M in 2025, up $15.1M YoY from $110.5M in 2024, driven by Alexion and Incyte license agreements
- Operating loss $177.5M in 2025, nearly flat vs $178.4M in 2024, representing an operating margin of -141.3% vs -161.4%
- Best segment Royalties $80.3M in 2025, up $12.8M YoY; worst segment License revenues $0 in 2025 vs $8.5M in 2024
- Management emphasizes disciplined portfolio management and clinical data-driven strategy; no explicit forward guidance stated
AI summary of the XNCR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly updated legal risk: Merus patent disputes resolved July 2026, including dismissal with prejudice and terminated inter partes reviews
- Financial benefit from settlement: $7.0 million cash payment received from Merus in July 2026
- Intellectual-property risk: Future infringement claims could require royalties, licensing, treble damages, or commercialization cessation
- Operational risk: Patent litigation could divert management time and resources from product development and commercialization
- Carried-forward competitive risk: Larger competitors may sustain complex patent-litigation costs more effectively due to greater resources
Management Discussion & Analysis
- Quarterly revenue $116.5M, up $95.5M YoY, driven by royalty and milestone recognition
- Operating margin 19.6% vs negative 226.3% YoY, with operating income $22.9M vs loss of $47.5M
- Best revenue contributor: Alexion royalties $83.5M vs $18.7M YoY
- R&D expenses $84.3M, up $29.9M YoY, led by XmAb942 external costs of $11.8M
- Cash, equivalents and marketable debt securities $555.7M vs $610.8M at December 31, 2025, with nine-month operating cash flow of negative $120.6M
AI summary of the XNCR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release containing results attached as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $116.5M vs $21.0M, driven by Alexion and Incyte royalties plus Astellas milestone revenue
- Net income $39.4M, or $0.50 diluted EPS, versus $6.0M loss and $(0.08) EPS in Q3 2025
Item 8.01: Other Events
- Updated Phase 1 XmAb819 results in advanced clear cell renal cell carcinoma
- XmAb819: ENPP3 x CD3 T-cell engaging bispecific antibody
Item EX-99.2: Item EX-99.2
- XmAb819 selected at 400 mcg/kg IV, with 45.5% cORR, 55% uORR and 82% six-month PFS in 11 evaluable patients
- Activity observed in heavily pretreated ccRCC, including 45% cORR after PD-(L)1 plus at least two VEGFR TKIs
Item EX-99.1: Item EX-99.1
- XmAb819 showed dose-dependent activity in heavily pretreated ccRCC: confirmed ORR 30% at 100 μg/kg, 44% at 200 μg/kg, and 45.5% at 400 μg/kg
- Activity extended to resistant populations, with ORR 34.8% after prior HIF2α inhibitors and 45.2% after ≥2 VEGFR-TKIs
Item 2.02: Results of Operations and Financial Condition
- Cash runway extended into 2029 under current operating plans, supporting continued research and development funding
- Runway depends on clinical-trial costs, timing and outcomes, operating changes, and collaboration or licensing revenue
Item 7.01: Regulation FD Disclosure
- Xencor disclosed updated Phase 1 XmAb819 results in advanced clear cell renal cell carcinoma
- XmAb819 is an ENPP3 x CD3 T-cell engaging bispecific antibody
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced by Xencor
- Financial details and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q2 revenue $51.2M, up from $43.6M, boosted by $27.6M recognized from the Alexion royalty settlement
- Additional Alexion settlement consideration $77.4M expected in Q3, providing near-term cash and revenue support
AI summaries of XNCR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for XNCR
Don't miss the next XNCR filing
- Alerts as it files. A push when XNCR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut XNCR, by share count.
- Ask anything. An AI agent that reads every XNCR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cornelissen Bart Jan | Sell | Nov 11, 2026 | 10,100 | $39.82 |
| RANIERI RICHARD J | M | Nov 10, 2026 | 15,000 | - |
| RANIERI RICHARD J | M | Nov 10, 2026 | 15,000 | $23.04 |
| RANIERI RICHARD J | M | Nov 10, 2026 | 11,971 | $21.31 |
| RANIERI RICHARD J | Sell | Nov 10, 2026 | 70,080 | $39.20 |
| RANIERI RICHARD J | Sell | Nov 10, 2026 | 11,172 | $39.59 |
| RANIERI RICHARD J | M | Nov 10, 2026 | 27,372 | $9.43 |
| RANIERI RICHARD J | M | Nov 10, 2026 | 21,412 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $110.5M | $125.6M |
| Operating Income | - | -$178.4M | -$177.5M |
| Net Income | -$126.1M | -$232.6M | -$91.9M |
| Op. Margin | - | -161.5% | -141.4% |
| Net Margin | - | -210.5% | -73.2% |
| Balance Sheet | |||
| Total Assets | $952.7M | $951.9M | $875.5M |
| Equity | - | $677.6M | $635.6M |
| ROE | - | -34.3% | -14.5% |
| Per Share | |||
| EPS | $-2.08 | $-3.58 | $-1.24 |
| Cash Flow | |||
| Operating CF | - | -$202.2M | -$135.1M |
| CapEx | $18.4M | $6.1M | $3.1M |
Source: XBRL data in Xencor Inc (XNCR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate XNCR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $865.9M |
| Q2 2026 | 31 | $585.8M |
| Q1 2026 | 30 | $418.9M |
| Q4 2025 | 28 | $519.8M |
| Q3 2025 | 29 | $403.0M |
| Q2 2025 | 29 | $292.6M |
| Q1 2025 | 27 | $209.0M |
| Q4 2024 | 20 | $381.8M |
- Invesco Ltd+610.3K (+234%)
- Goldman Sachs Group+445.1K (+46%)
- Bank of America Corp+264.0K (+73%)
- Dimensional Fund Advisors+72.1K (+7%)
- Morgan Stanley+51.8K (+3%)
- BlackRock−1.24M (-9%)
- State Street Corp−797.3K (-16%)
- Vanguard Portfolio Management LLC−408.5K (-18%)
- Citadel Advisors LLC−150.1K (-79%)
- Citigroup−136.4K (-82%)
- FMR LLC (Fidelity)−119.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 225 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
XNCR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 26, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
XNCR SEC filings: frequently asked questions
Are XNCR insiders buying or selling?
In the last 90 days, Xencor Inc (XNCR) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $3.6 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold XNCR stock?
As of September 30, 2026, the largest Xencor Inc (XNCR) holders among the 13F filers tracked by SignalX were BlackRock ($309.6 million), State Street Corp ($103.7 million), Vanguard Capital Management LLC ($79.9 million), T. Rowe Price Group ($57.7 million), Vanguard Portfolio Management LLC ($45.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was XNCR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Xencor Inc (XNCR) reported revenue of $125.6 million (up 13.7% from FY2024) and a net loss of $91.9 million. Diluted EPS was -$1.24. The figures come from the XBRL data in the 10-K.
What are the main risks in XNCR's latest 10-K?
In the 10-K filed February 25, 2026, Xencor Inc (XNCR) flagged: Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates. Geopolitical/macro risk from California concentration; wildfires or earthquakes could disrupt operations and third-party supply continuity. (AI summary of the Risk Factors section.)
What did XNCR report in its latest 8-K?
Xencor Inc (XNCR) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest XNCR SEC filings?
Xencor Inc (XNCR) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.
What is XNCR's SEC CIK number?
Xencor Inc (XNCR)'s SEC Central Index Key (CIK) is 1326732. EDGAR lists every XNCR filing under that number.
Ask anything about XNCR
The research agent reads XNCR's filings, financials, insider trades and 13F holders, then answers with sources.